Monarch Partners Asset Management’s Castle Biosciences CSTL Stock Holding History

Monarch Partners Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$4.01M	Sell	170,195 -18,436	-10%	-$427K	1.18%	21
2022 Q3	$4.92M	Buy	188,631 +55,589	+42%	+$1.56M	1.48%	7
2022 Q2	$2.92M	Sell	133,042 -23,460	-15%	-$545K	0.82%	47
2022 Q1	$7.02M	Buy	156,502 +41,838	+36%	+$1.73M	1.57%	3
2021 Q4	$4.92M	Sell	114,664 -47,804	-29%	-$2.5M	1%	22
2021 Q3	$10.8M	Buy	162,468 +8,581	+6%	+$604K	1.58%	3
2021 Q2	$11.3M	Buy	153,887 +140,227	+1,027%	+$9.26M	1.62%	3
2021 Q1	$935K	Sell	13,660 -65,272	-83%	-$4.91M	0.14%	137
2020 Q4	$5.3M	Sell	78,932 -17,922	-19%	-$972K	0.93%	43
2020 Q3	$4.98M	Buy	96,854 +74,039	+325%	+$3.29M	1.12%	30
2020 Q2	$860K	Buy	22,815 +7,415	+48%	+$253K	0.21%	101
2020 Q1	$459K	Buy	15,400 +5,230	+51%	+$158K	0.16%	117
2019 Q4	$350K	Sell	10,170 -6,420	-39%	-$157K	0.08%	167
2019 Q3	$300K	Buy	+16,590	New	+$368K	0.05%	164

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Monarch Partners Asset Management's CSTL Position: Q4 2022 in Review

Monarch Partners Asset Management reduced its Castle Biosciences (CSTL) stake by 9.8% in Q4 2022, selling an estimated $427K and leaving 170,195 shares worth $4.01M. The position accounts for 1.18% of the portfolio, ranked #21.

Monarch Partners Asset Management first reported a position in CSTL in Q3 2019 and has held it in 14 quarters since. The position peaked at $11.3M in Q2 2021. 153 funds tracked by Wall St. Rank hold CSTL as of Q4 2022.

Monarch Partners Asset Management held 170,195 shares of Castle Biosciences worth $4.01M as of Q4 2022.
Monarch Partners Asset Management sold 18,436 Castle Biosciences shares in Q4 2022, an estimated $427K.
Castle Biosciences made up 1.18% of Monarch Partners Asset Management's portfolio in Q4 2022, its #21 holding.
Monarch Partners Asset Management first reported a position in Castle Biosciences in Q3 2019 and has held it in 14 quarters since.
Monarch Partners Asset Management's Castle Biosciences position peaked at $11.3M in Q2 2021.
153 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2022.

Based on Monarch Partners Asset Management's 13F filing for Q4 2022, filed 2 Feb 2023.